Abliva AB (publ) (NEVPF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -95.5 Million SEK | -15.77% |
| 2022 | -8.14 Million USD | 40.11% |
| 2021 | -13.59 Million USD | -86.14% |
| 2020 | -7.3 Million USD | 11.19% |
| 2019 | -8.22 Million USD | -6.65% |
| 2018 | -7.71 Million SEK | 5.37% |
| 2017 | -8.14 Million SEK | -5.41% |
| 2016 | -7.73 Million SEK | 27.67% |
| 2015 | -10.68 Million SEK | 74.88% |
| 2014 | -42.54 Million SEK | -90.54% |
| 2013 | -22.33 Million SEK | -50.14% |
| 2012 | -14.87 Million SEK | -58.46% |
| 2011 | -9.38 Million SEK | -96.62% |
| 2010 | -4.77 Million SEK | -212.31% |
| 2009 | -1.52 Million SEK | 1.87% |
| 2008 | -1.55 Million SEK | -26.93% |
| 2007 | -1.22 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.41 Million USD | -41.62% |
| 2024 Q1 | -1.69 Million USD | 27.95% |
| 2023 FY | -9.42 Million USD | -15.77% |
| 2023 Q2 | -1.95 Million USD | -26.95% |
| 2023 Q3 | -3 Million USD | -53.4% |
| 2023 Q4 | -2.49 Million USD | 17.12% |
| 2023 Q1 | -1.54 Million USD | 8.06% |
| 2022 Q2 | -2 Million SEK | 14.51% |
| 2022 Q3 | -2.25 Million USD | -12.68% |
| 2022 Q4 | -1.67 Million USD | 25.52% |
| 2022 FY | -8.14 Million USD | 40.11% |
| 2022 Q1 | -2.33 Million SEK | 42.37% |
| 2021 Q3 | -3.96 Million SEK | -11.9% |
| 2021 Q4 | -4.05 Million SEK | -2.35% |
| 2021 Q1 | -2.46 Million SEK | 81.16% |
| 2021 Q2 | -3.54 Million SEK | -43.99% |
| 2021 FY | -13.59 Million USD | -86.14% |
| 2020 Q3 | -10.07 Million SEK | 50.38% |
| 2020 Q4 | -13.06 Million SEK | -29.62% |
| 2020 FY | -7.3 Million USD | 11.19% |
| 2020 Q1 | -16.53 Million SEK | 38.99% |
| 2020 Q2 | -20.31 Million SEK | -22.83% |
| 2019 Q2 | -20.76 Million SEK | -50.25% |
| 2019 FY | -8.22 Million USD | -6.65% |
| 2019 Q1 | -13.82 Million SEK | 6.97% |
| 2019 Q3 | -15.29 Million SEK | 26.34% |
| 2019 Q4 | -27.1 Million SEK | -77.2% |
| 2018 Q1 | -13.05 Million SEK | -31.79% |
| 2018 Q2 | -25.48 Million SEK | -95.23% |
| 2018 Q3 | -14.98 Million SEK | 41.2% |
| 2018 Q4 | -14.85 Million SEK | 0.83% |
| 2018 FY | -7.71 Million SEK | 5.37% |
| 2017 Q4 | -9.9 Million SEK | 24.39% |
| 2017 Q3 | -13.09 Million SEK | 41.16% |
| 2017 Q2 | -22.26 Million SEK | -34.18% |
| 2017 Q1 | -16.59 Million SEK | -17.25% |
| 2017 FY | -8.14 Million SEK | -5.41% |
| 2016 Q2 | -11.58 Million SEK | -9.44% |
| 2016 Q1 | -10.58 Million SEK | -55.29% |
| 2016 Q3 | -34.29 Million SEK | -195.99% |
| 2016 FY | -7.73 Million SEK | 27.67% |
| 2016 Q4 | -14.15 Million SEK | 58.73% |
| 2015 Q1 | -14.01 Million SEK | 14.09% |
| 2015 Q3 | -53.66 Million SEK | -243.52% |
| 2015 Q4 | -6.81 Million SEK | 87.3% |
| 2015 Q2 | -15.62 Million SEK | -11.51% |
| 2015 FY | -10.68 Million SEK | 74.88% |
| 2014 Q4 | -16.3 Million SEK | -372.56% |
| 2014 FY | -42.54 Million SEK | -90.54% |
| 2014 Q1 | -9.56 Million SEK | -12.03% |
| 2014 Q2 | -13.22 Million SEK | -38.26% |
| 2014 Q3 | -3.45 Million SEK | 73.91% |
| 2013 Q1 | -4.52 Million SEK | 4.27% |
| 2013 FY | -22.33 Million SEK | -50.14% |
| 2013 Q4 | -8.53 Million SEK | -33.43% |
| 2013 Q3 | -6.39 Million SEK | -123.12% |
| 2013 Q2 | -2.86 Million SEK | 36.63% |
| 2012 Q2 | -3.84 Million SEK | -46.89% |
| 2012 Q1 | -2.61 Million SEK | -3.6% |
| 2012 FY | -14.87 Million SEK | -58.46% |
| 2012 Q4 | -4.72 Million SEK | -28.51% |
| 2012 Q3 | -3.67 Million SEK | 4.37% |
| 2011 Q4 | -2.52 Million SEK | -8.49% |
| 2011 FY | -9.38 Million SEK | -96.62% |
| 2011 Q2 | -3.03 Million SEK | -118.53% |
| 2011 Q1 | -1.38 Million SEK | -3.81% |
| 2011 Q3 | -2.33 Million SEK | 23.13% |
| 2010 Q1 | -837.64 Thousand SEK | -103.21% |
| 2010 FY | -4.77 Million SEK | -212.31% |
| 2010 Q3 | -1.45 Million SEK | -27.11% |
| 2010 Q2 | -1.14 Million SEK | -36.67% |
| 2010 Q4 | -1.33 Million SEK | 8.18% |
| 2009 FY | -1.52 Million SEK | 1.87% |
| 2009 Q2 | -426.59 Thousand SEK | -11.97% |
| 2009 Q1 | -380.97 Thousand SEK | 0.0% |
| 2009 Q3 | -308.72 Thousand SEK | 27.63% |
| 2009 Q4 | -412.2 Thousand SEK | -33.52% |
| 2008 FY | -1.55 Million SEK | -26.93% |
| 2007 FY | -1.22 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | -2131.518% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -27.408% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -34833.541% |
| SQZ Biotechnologies Company | -79.46 Million USD | -20.192% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -3202.074% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 280.277% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 246.637% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -5146.225% |
| Marizyme, Inc. | -65.34 Million USD | -46.157% |
| Genus plc | 7.9 Million USD | 1308.975% |
| Pharming Group N.V. | -10.54 Million USD | -805.47% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -4301.714% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -2474.204% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -979.93% |
| ContraFect Corporation | -65.15 Million USD | -46.592% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -5428.885% |
| IMV Inc. | -36.48 Million USD | -161.771% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -1085.022% |
| ONE Bio Corp. | 8.67 Million USD | 1200.764% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -84.766% |
| Mesoblast Limited | -87.95 Million USD | -8.587% |
| MultiCell Technologies, Inc. | -380.07 USD | -25129218.283% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -2458.505% |
| Genscript Biotech Corporation | -95.47 Million USD | -0.034% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -15002.458% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -3911.517% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -1352.363% |
| Biomind Labs Inc. | -1.21 Million USD | -7765.231% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -2979.179% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -1108.502% |
| Skye Bioscience, Inc. | -37.64 Million USD | -153.711% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -4799.784% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -776.894% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -637647.062% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -1854.723% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -1267.768% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -501.766% |
| Accustem Sciences Inc. | -3.74 Million USD | -2449.341% |
| EV Biologics, Inc. | -1.26 Million USD | -7437.403% |
| Q BioMed Inc. | -2.05 Million USD | -4554.224% |
| GB Sciences, Inc. | -1.36 Million USD | -6914.072% |
| Alpha Cognition Inc. | -13.77 Million USD | -593.473% |
| CSL Limited | 2.64 Billion USD | 103.615% |
| Agentix Corp. | -1.37 Million USD | -6850.097% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -59.914% |
| Enzolytics Inc. | -2.17 Million USD | -4287.523% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -3.61 Million USD | -2545.679% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -2911.538% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -1541.823% |
| argenx SE | -295.05 Million USD | 67.63% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -52.573% |
| HST Global, Inc. | -146.21 Thousand USD | -65223.165% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 97558.163% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -5342.818% |
| Halberd Corporation | -79.67 Thousand USD | -119771.731% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 1479.272% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -3056.138% |
| Zenith Capital Corp. | -10.59 Million USD | -801.368% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -2303.956% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -2203.678% |
| AVAX Technologies, Inc. | -6.41 Million USD | -1389.153% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -157921.238% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -4663.268% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -410832.794% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | -1902.626% |
| Helix BioMedix, Inc. | -1.05 Million USD | -8943.925% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -2400.89% |
| Kadimastem Ltd | -3.3 Million USD | -2787.738% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | -1025.889% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -21539.263% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -7051.923% |
| LadRx Corporation | 400.44 Thousand USD | 23950.835% |
| Cell Source, Inc. | -5.32 Million USD | -1694.873% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -22887.684% |
| Regen BioPharma, Inc. | 1.02 Million USD | 9431.534% |
| Regen BioPharma, Inc. | 1.02 Million USD | 9431.534% |
| Affymax, Inc. | -14.42 Million USD | -562.153% |
| Mobile Lads Corp. | -2.26 Million USD | -4119.915% |
| Itoco Inc. | -1.86 Million USD | -5010.18% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -2049.876% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -5622.528% |
| International Stem Cell Corporation | -131 Thousand USD | -72807.634% |
| CytoDyn Inc. | -49.84 Million USD | -91.627% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -120746.988% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -41766.592% |
| Qrons Inc. | -789.34 Thousand USD | -11999.748% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -10044.032% |
| SYBLEU INC | -180.3 Thousand USD | -52871.093% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -4474.883% |
| Rebus Holdings, Inc. | -1.02 Million USD | -9263.627% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -5822.168% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -175882.09% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -3674.691% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -98.679% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -4417.928% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -12130.835% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -2914.804% |
| Neutra Corp. | -233.46 Thousand USD | -40809.344% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -370.696% |
| PureTech Health plc | -65.69 Million USD | -45.378% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -349.105% |
| IXICO plc | -1.17 Million USD | -8007.725% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -862.113% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -67.184% |
| CSL Limited | 2.64 Billion USD | 103.615% |
| Cellectis S.A. | -103.17 Million USD | 7.429% |